| Effects of storage media, supplements and cryopreservation methods on quality of stem cells OD Erol, B Pervin, ME Seker, F Aerts-Kaya World Journal of Stem Cells 13 (9), 1197, 2021 | 27 | 2021 |
| Development, characterization, and hematopoietic differentiation of Griscelli syndrome type 2 induced pluripotent stem cells G Güney-Esken, ÖD Erol, B Pervin, G Gürhan Sevinç, T Önder, E Bilgiç, ... Stem cell research & therapy 12 (1), 287, 2021 | 4 | 2021 |
| The Role of Rab GTPases in the development of genetic and malignant diseases ÖD Erol, Ş Şenocak, F Aerts-Kaya Molecular and cellular biochemistry 479 (2), 255-281, 2024 | 2 | 2024 |
| Biomedical Efficacy of Garlic‐Extract‐Loaded Core‐Sheath Plasters for Natural Antimicrobial Wound Care H Majd, M Gultekinoglu, C Bayram, B Karaosmanoğlu, EZ Taşkıran, ... Macromolecular Materials and Engineering, 2400014, 2024 | 1 | 2024 |
| Non-Myelotoxic Agents as a Preparatory Regimen for Hematopoietic Stem Cell Gene Therapy ME ŞEKER, ÖD EROL, B PERVİN, G Wagemaker, NP van Til, ... | 1 | 2023 |
| Bone marrow mesenchymal stromal cells support regeneration of intestinal damage in a colitis mouse model, independent of their CXCR4 expression B Pervin, M Gizer, ME Şeker, ÖD Erol, SN Gür, EG Polat, B Değirmenci, ... Clinical and Translational Science 17 (5), e13821, 2024 | | 2024 |
| P1371: COMPARISON OF DIFFERENT METHODS FOR GENETIC CORRECTION OF GRISCELLI SYNDROME TYPE II-DERIVED STEM CELLS ÖD Erol, B Pervin, ME Şeker, B Özçimen, Ş Şenocak, SN Gür, HB Kiliç, ... HemaSphere 7 (S3), e37198af, 2023 | | 2023 |
| P1372: NON-MYELOTOXIC CHEMICALS AS A PREPARATORY REGIMEN FOR HEMATOPOIETIC STEM CELL GENE THERAPY MEİ Şeker, ÖD Erol, B Pervİn, G Wagemaker, NPVAN Til, F Aerts-Kaya HemaSphere 7 (S3), e6316019, 2023 | | 2023 |
| Correction of RAB27A gene from Griscelli Syndrome Type II derived Mesenchymal Stem Cells OD Erol, ME Seker, NP Van Til, F Aerts-Kaya HUMAN GENE THERAPY 32 (19-20), A135-A135, 2021 | | 2021 |
| Using bone marrow permeabilisation instead of chemotherapy as a conditioning regimen for HSC gene therapy of RAG2-SCID ME Seker, OD Erol, B Pervin, F Aerts-Kaya HUMAN GENE THERAPY 32 (19-20), A135-A135, 2021 | | 2021 |
| Uyarılmış Pluripotent Kök Hücrelerle nadir hastalık modellemesi ÖD Erol, ME Şeker, F Aerts-Kaya Türkiye Klinikleri Tıbbi Genetik-Kök Hücre ve Rejeneratif Tıp 3 (978-625-401 …, 2021 | | 2021 |
| Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases and Its Implications for Future Gene Therapy Trials in Turke E Güney, Ö Erol, F AERTS KAYA Trakya University Journal of Natural Sciences 20, 2020 | | 2020 |
| Repair of Griscelli Type 2 mesenchymal stem cells with a lentiviral vector carrying RAB27Aco Ö EROL, M ŞEKER, B Pervin, N van Til, A ÖZCAN, Y KOCAEFE, ... | | |
| Development and Differentiation of Induced Pluripotent Stem Cells from Griscelli type 2 patients G Güney Esken, Ö Erol, F AERTS KAYA | | |
| RAG2-/-ağır kombine immün yetmezliği hematopoetik kök hücre nakli ve gen tedavi optimizasyonu. Ö Erol, F ÇETİNKAYA, G Wagemaker, F AERTS KAYA | | |
| Neuropeptide Y plays a role in the regulation of proliferation and quiescence of HSCs Ö EROL, M ŞEKER, B PERVİN, Ö ÖZYÜNCÜ, T YANIK, F AERTS KAYA | | |
| Hematopoetik Kök Hücre Naklinde Alıcıya Zarar Vermeyen Hazırlık Rejimlerinin Geliştirilmesi M ŞEKER, Ö EROL, B PERVİN, F AERTS KAYA | | |
| WJSC AN Sant'Ana, AB Araújo, FDC Gonçalves, AH Paz, A Goutas, V Trachana, ... | | |
| Use of Mesenchymal Stem Cells in COVID-19 ÖD Erol, F Aerts-Kaya | | |
Fatima Aerts KayaHacettepe UniversityVerified email at hacettepe.edu.tr
